TY  - JOUR
T1  - The Biological Identity Ledger for Tracing Protein Corona Formation, Immune Recognition, Tissue Distribution, and Nanocarrier Fate
A1  - Kristian Eriksen
A1  - Solveig Berg
A1  - Magnus Dahl
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2025
VL  - 14
IS  - 2
DO  - 10.51847/QvyuCebgyC
SP  - 35
EP  - 44
N2  - Nanocarriers are commonly defined by properties measured before administration, yet their biologically operative identity changes as they encounter proteins, lipids, antibodies, cells, extracellular matrices, and intracellular environments. Fragmented reporting of manufactured attributes, acquired coronas, recognition events, tissue exposure, degradation, and clearance prevents these transformations from being traced as one evidence chain. This Original Evidence Architecture Article proposes the Biological Identity Ledger, a non-empirical scientific traceability architecture that links batch-resolved synthetic identity and manufacturing provenance to biological exposure events, acquired corona states, immune-recognition states, and fate states. Its central principle is that nanocarrier identity is neither a single static descriptor nor equivalent to efficacy: it is a versioned, compartment- and time-indexed record whose interpretation depends on measurement method, biological context, and uncertainty. The architecture introduces eight linked constructs: the Synthetic Identity Record, Manufacturing Provenance Record, Biological Exposure Event, Acquired Corona State, Recognition State, Fate State, Temporal-Compartment Key, and Evidence Provenance and Uncertainty Layer. Temporal updating is used to represent corona exchange, barrier transitions, intracellular remodeling, payload release, degradation, and clearance without presuming a universal causal sequence. Evidence provenance separates observation from inference and records analytical recovery limits, biological variability, and transferability constraints. Validation would require schema testing, longitudinal and multi-compartment experiments, batch-linked manufacturing studies, human-matrix and species-aware comparisons, interlaboratory reproducibility, and prospective assessment before decision use. The proposed ledger is an original conceptual synthesis for organizing testable relationships and reporting requirements; it is not a validated predictive model, clinical recommendation, regulatory standard, or deployment-ready system.
UR  - https://ijpras.com/article/the-biological-identity-ledger-for-tracing-protein-corona-formation-immune-recognition-tissue-dist-cj67zju6ayiduv7
ER  -